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Available online 27 May 2016Background: The acidic subunit of amarantin (AAC)—the predominant amaranth seed storage protein—has
functional potential and its third variable region (VR) has been modiﬁed with antihypertensive peptides to
improve this potential. Here, we modiﬁed the C-terminal in the fourth VR of AAC by inserting four VY
antihypertensive peptides. This modiﬁed protein (AACM.4) was expressed in Escherichia coli. In addition, we
also recombinantly expressed other derivatives of the amarantin protein. These include: unmodiﬁed
amarantin acidic subunit (AAC); amarantin acidic subunit modiﬁed at the third VR with four VY peptides
(AACM.3); and amarantin acidic subunit doubly modiﬁed, in the third VR with four VY peptides and in the
fourth VR with the RIPP peptide (AACM.3.4).
Results: E. coli BL21-CodonPlus (DE3)-RIL was themost favorable strain for the expression of proteins. After 6 h of
induction, it showed the best recombinant protein titer. The AAC and AACM.4 were obtained at higher titers
(0.56 g/L) while proteins modiﬁed in the third VR showed lower titers: 0.44 g/L and 0.33 g/L for AACM.3 and
AACM.3.4, respectively. As these AAC variants were mostly expressed in an insoluble form, we applied a
refolding protocol. This made it possible to obtain all proteins in soluble form. Modiﬁcation of the VR 4
improves the thermal stability of amarantin acidic subunit; AAC manifested melting temperature (Tm) at 34°C
and AACM.4 at 37.2°C. The AACM.3 and AACM.3.4 did not show transition curves.
Conclusions:Modiﬁcations to the third VR affect the thermal stability of amarantin acidic subunit.
© 2016 Pontiﬁcia Universidad Católica de Valparaíso. Production and hosting by Elsevier B.V. All rights reserved.Keywords:
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Hypertension is a worldwide health problem and is a major risk
factor for cardiovascular diseases such as heart failure, stroke,
peripheral arterial disease and myocardial infarction. Some drugs
developed for hypertension treatment cause side effects including
the angiotensin converting enzyme (ACE) inhibitors. They inhibit
the conversion of angiotensin I to angiotensin II within the
renin-angiotensin system. Because of this, several researchers have
focused on the study of new alternatives including nutritive
compounds that contribute to the treatment of hypertension. These
include bioactive peptides that are usually composed of 2–20 amino
acid residues but may be larger [1,2,3]. These structures have been
isolated from different foods and are usually inactive within theipn.mx (S. Luna-Suárez).
idad Católica de Valparaíso.
araíso. Production and hosting by Elsequences of parent proteins but can be released by enzymatic
hydrolysis during gastrointestinal digestion or during food preparation
to subsequently acquire bioactivity [4,5]. Other strategies to obtain
these products include the design of antihypertensive peptide
multimers or protein engineering. Biopeptides can be introduced into
proteins with nutritional or functional importance, and these new
structures may be used as components in foods or additives in the
formulation of new products [6,7]. An alternative to synthesizing
these proteins is through recombinant systems such as Escherichia coli
because the genetic manipulation is easy, culture is inexpensive, and
expression is fast to quickly produce large amounts of protein [8].
In our group, we puriﬁed and characterized the amarantin acidic
subunit (AAC) by expressing it in E. coli. Amarantin is important
because of its nutritional value, it has an excellent essential amino acid
balance; the AAC is a good candidate for modiﬁcation in terms of its
structure [9], it harbors four variable regions on the molecular surface
(Fig. 1). The variable regions have been suggested as suitable targets
for modiﬁcation because they are not important in the structuresevier B.V. All rights reserved.
Fig. 1. Schematic representation of AAC variants and putative 3Dmodel. (a) AAC variants previously reported and variant generated in this research (AACM.4). Four variable regions are
indicated inAAC scheme by VR1, VR2, VR3 andVR4; residue numbering is based on the PDB structure of amaranth 11S proglobulin seed storageprotein from A. hypochondriacus L. (3QAC);
white and black areas represent conserved and variable regions, respectively. Numbers in the second to fourth schemes indicate insertion in each protein. (b), putative 3Dmodel using as
template 11S globulin from amaranth (PDB 3QAC). Variable regions are indicated with VR1, VR2, VR3, and VR4 that correspond with unordered structure exposed in surface.
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four Val-Tyr (VY) antihypertensive peptides into the AAC third
variable region (VR) to improve its nutraceutical properties [11]. We
also generated and overexpressed the doubly modiﬁed acidic subunit
(AACM.3.4) into the third VR with four VY and a RIPP peptide at the
C-terminal [12]. This last protein showed antihypertensive effect both
in in vitro and in vivo trials [13]. The objective of this research was to
modify AAC by inserting four VY antihypertensive peptides into
the C-terminal to generate the protein AACM.4; and to compare
expression levels and thermal stability of the new protein and the
above mentioned variants of AAC. This might lead to the identiﬁcation
of a good candidate or model to establish the basis for the production
of a functional food additive or to improve the nutraceutical
properties in some crops in the near future.2. Materials and methods
Fig. 1a is a schematic diagram that summarizes the proteins used in
this work.2.1. Homology modeling of AAC
In order to evaluate the spatial positioning of the variable regions, a
3D model was generated using amaranth 11S globulin (PDB 3QAC) as
template [14] and RaptorX server [15] which predict secondary and
tertiary structures together with disordered regions. Moreover, as VRs
in 3QAC are disordered regions, which are not visible in the crystal
structure, the model of AAC generated by RaptorX was optimized
using ModLoop server (https://modbase.compbio.ucsf.edu/modloop/)
which is a software tool used to predict disordered regions by
satisfaction of spatial restraints. Then, the resulting homology 3D
model suggests that the VRs are exposed on the surface (Fig. 1b).2.2. Construction of the modiﬁed amarantin acidic subunit expression
plasmid to express AACM.4
The plasmid pET-ACID-R4-6His that codes for AACM.4 was
constructed from pET-AC-6His [9] which contains the cDNA that
codiﬁes amarantin acidic subunit. This plasmid is derived from
pSPORT-11S, which contains the cDNA that codiﬁes amaranth 11S
globulin (GenBank accession no. CAA57633.1) [16]. pET-AC-6His was
used as PCR template for carrying out site-directed mutagenesis to
insert four VY biopeptides in tandem into the fourth variable region
corresponding to the C-terminal region in the AAC. Platinum® Taq
DNA Polymerase High Fidelity (Invitrogen) was used to obtain the
PCR products of AAC mutated into its fourth variable region. The
primers for ampliﬁcation were: forward 5′-TGGGTGATTAATGGAAGG
AAGG-3′ (underlined corresponding to the AseIrestriction site that
enabled cloning into the pET-32b(+) vector). Reverse: 5′-CTCGAG
GTAAACGTAAACGTATACGTAAACCCTATTGGGAAGG-3′ (the encoding
sequence of the VYVYVYVY peptide inserted in bold letters, with Xho I
restriction site underlined). This enabled cloning into the pET-32b(+)
vector.
Following ampliﬁcation, the PCR product was cloned into
pPCR®2.1-TOPO®. E. coli cells harboring recombinant plasmid were
selected on LB plates containing 100 μg/mL ampicillin and X-gal. The
DNA fragment encoding AACM.4 was released from pPCR®2.1-TOPO
vector using VspI and XhoI restriction enzymes. The VspI restriction
site enabled cloning the region of AACM.4 into the ribosome binding
site in the pET-32b(+) vector. The split by XhoI enabled cloning of
AACM.4 onto the frame with the His tag region of the vector. The
VspI/XhoI fragment was ligated into plasmid pET-32b(+) and
transformed into the TOP 10 cloning host as described by Sambrook
et al. [17]. The E. coli transformants were selected on LB plates
containing 100 μg/mL carbenicillin. The positive clones were
conﬁrmed with PCR, restriction analysis and DNA sequencing using
both T7 forward and reverse sequencing primers.
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E. coli, Rosetta 2 and BL21-CodonPlus(DE3)-RIL strains were
transformed with pET-AC-6His codifying AAC [9], pET-AC-M1
codifying AACM.3 [11], pET-ACID-R4-6His codifying AACM.4, and
pET-AC-M3-6His codifying AACM.3.4 [12] by applying heat shock
following the manufacturer's instructions. All used plasmids contained
an ampicillin resistance gene (AmpR) it makes the E. coli strain
ampicillin resistant. Subsequently, successfully transformed cells were
selected on LB (Sigma) agar plates containing 100 μg/mL ampicillin
and 34 μg/mL chloramphenicol.2.4. Inoculum preparation and shake ﬂask fermentation
Transformants expressing AAC and its variants were used to
inoculate 5 mL LB broth (Sigma) supplemented with appropriate
antibiotics as mentioned previously. Pre-cultures were grown
overnight at 37°C on an orbital shaker at 200 rpm. Shake ﬂask
fermentations were performed in 250 mL Erlenmeyer ﬂasks
containing 42 mL of LB broth. Cultivations were inoculated with
2.5% (v/v) pre-culture. Cultures were shaken at 200 rpm in an orbital
incubator at 37°C. Expression of different variants of AAC (in both
strains) were initiated when cultures reached 0.5 OD at 600 nm
by adding lactose as an inducer at 0.5% (w/v) according toFig. 2. SDS-PAGE andWestern blot of recombinant proteins. (a) AAC protein and schematic rep
representation; (d) AACM.3.4 protein and schematic representation. The four variable regions
weight; 1: 0 h of induction; 2: 1.5 h of induction; 3: 3 h of induction; 4: 6 h of induction; 5: 24 h o
9: 24 h of induction in E. coliBL21-CodonPlus(DE3)-RIL. The image below corresponds toWeste
in each SDS-PAGE gels. 5 μg of protein was loaded into each lane.Morales-Camacho et al. [18]. This process was continued after
induction and samples were taken at 0, 1.5, 3, 6, and 24 h to
determine the best strain to express all variants of AAC; 1 mL from
each culture was transferred to 1.5 mL centrifuge tube. All samples
were harvested by centrifugation at 13,300 × g for 5 min at room
temperature. Supernatants were discarded and cell pellets were
stored at -20°C for further analysis.2.5. Bioreactor fermentation
To increase the production yield of AAC and its variants, the
fermenter cultures were performed in a 5 L bioreactor Biostat
A (Sartorius) with an 80% working volume as described in
Morales-Camacho et al. [18] with some modiﬁcations. For each
expression experiment, (AAC, AACM.3, AACM.4, and AACM.3.4) batch
culture conditions were as follows: culture media, 4 L (200 g/L potato
waste, 12 g/L tryptone, 4 g/L glycerol, 17 mM KH2PO4 and 72 mM
K2HPO4); inoculum, 2.5% (v/v); agitation, 340 rpm; aeration, 1 vvm;
pH was maintained at 7 by addition of 2 M NaOH or 5 M H2SO4; initial
temperature, 37°C and subsequent induction temperature was
adjusted to 30°C. Protein expression was induced when the culture
had an OD600 of 0.5 with 0.5% (w/v) lactose. The cells were harvested
6 h after induction by centrifugation 13,300 × g for 5 min at room
temperature.resentation; (b) AACM.3 protein and schematic representation; (c) AACM.4 and schematic
are shown with labels I, II, III, and IV. The modiﬁcation is indicated. Lanes: MW: molecular
f induction in E. coliRosetta 2; 6: 1.5 h of induction; 7: 3 h of induction; 8: 6 h of induction;
rn blot of each recombinant protein. Arrows indicate the presence of AAC and their variants
Fig. 3. Expression of recombinant proteins by E. coli BL21-CodonPlus(DE3)-RIL. (a) Yields achieved after induction; (b) productivity achieved in recombinant proteins after induction. Each
value is the mean of triplicate experiments. ANOVA analysis evaluated signiﬁcant differences in expression (P b 0.05).
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Cell pellets were resuspended in 0.25 mL of distilled water and
0.25 mL of loading buffer. Samples were analyzed by 12% SDS-PAGE
[19] and stained with Coomassie brilliant blue G-250. Western
blotting was used to detect the proteins, which were transferred to
PVDF membrane using a Mini Trans-Blot cell (Bio-Rad). Membrane
was incubated with a polyclonal antiamarantin as ﬁrst antibody, and
anti-rabbit conjugated to alkaline phosphatase as secondary antibody
in a dilution 1:60,000 and 1:3,000, respectively [9].2.7. Protein assay
Protein concentration was determined using BCA (bicinchoninic
acid) assay using bovine serum albumin (Sigma) as a protein
standard. The concentration of recombinant proteins was determined
in cell pellets disrupted in alkaline buffer (0.2 M NaOH, 1% SDS) and
by SDS-PAGE (12%) under denaturing and reducing conditions. GelsFig. 4. SDS-PAGE and Western blot of soluble and insoluble protein fraction in AAC,
BL21-CodonPlus(DE3)-RIL and Rosetta 2. (b) Extraction of AACM.4 and AACM.3.4 expressed
protein fraction and even lanes are the insoluble protein fraction. Arrows indicate recombinanwere scanned, and the area and intensity of the bands were quantiﬁed
by densitometric analysis using Image Lab 4.0 (Bio-Rad).
2.8. Experimental design
A simple factorial design for three factors was used to carry out
experiments for the expression of four recombinant proteins (AAC,
AACM.3, AACM.4, and AACM.3.4) in two E. coli strains (Rosetta 2 and
BL21-CodonPlus(DE3)-RIL) at different induction times (0, 3, 6, and
24 h). All trials were performed in triplicate.
The statistical software package Statgraphics 16.2.04 (Statistical
Graphics Corp) was used to analyze the data. An analysis of variance
(ANOVA) was used to assess the best strain to express AAC and the
modiﬁed variants according to protein titers.
2.9. Analysis of soluble and insoluble fraction of all variants of AAC
Cell disruption was used to determine the fraction in which each
variant of AAC was accumulated inside cells. The samples wereAACM.3, AACM.4, and AACM.3.4. (a) Extraction of AAC and AACM.3 expressed by
by BL21-CodonPlus(DE3)-RIL and Rosetta 2. Odd numbers in lanes represent the soluble
t proteins.
48 J.I. Morales-Camacho et al. / Electronic Journal of Biotechnology 22 (2016) 44–51harvested 6 h after induction and were used to induce cell disruption.
This treatment was carried out in 5 mL extraction buffer (EB) (0.2 M
NaCl, 20 mM phosphates, pH 7.5) applying sonication for 1 min at an
amplitude of 60% and then, kept on ice for 3 min. This process was
repeated six times. Subsequently, the disrupted cells were fractionated
by centrifugation at 15,600 × g for 30 min at 4°C. The supernatants
were discarded and the cell debris pellets were resuspended in 10 mL
solubilization buffer (SB) (6 M urea, 0.2 M NaCl, 20 mM phosphates,
pH 7.5) and shaken at 200 rpm and room temperature for 4 h.
Subsequently, the samples were centrifuged at 15,600 × g for 30 min
at 4°C to remove insoluble material. The supernatants were
recuperated and analyzed by 12% SDS-PAGE and stained with
Coomassie brilliant blue G-250 to detect recombinant proteins.
2.10. Puriﬁcation of AAC and its modiﬁed variants
The insoluble crude extract of each variant of AAC was applied to an
AP-2 20 × 300 mm column (Waters) packed with Protino Ni-TED resin
(Macherey–Nagel) coupled to BioLogic DuoFlow™ Chromatography
System (Bio-Rad) and eluted with buffer SB plus imidazole at a
ﬂow rate of 2.5 mL/min and at room temperature. Increasing
concentrations of imidazole were applied during puriﬁcation process
to evaluate which imidazole concentration eluted each variant of AAC.Fig. 5. SDS-PAGE andWestern blot of puriﬁcation and refolding process of recombinant proteins
weight; 1 and 4: soluble extract of each protein; 2 and 5: insoluble extract of each protein; 3 aFive column volumes of SB plus 5, 25, 50, 125, 250, and 500 mM
imidazole were passed through the column. All fractions collected
during the puriﬁcation process were analyzed by SDS-PAGE and
stored at 4°C.
2.11. Protein refolding of AAC and its modiﬁed variants
The refolding protocol was established to eliminate urea and allow
refolding of AAC, ACM.3, ACM.4, and ACM.3.4. First, 0.5 mL at 0.5 and
1 mg/mL for each sample of protein was dialyzed against 50 mL of
refolding buffer (4 M urea, 0.2 M NaCl, 20 mM phosphates, pH 7.5) for
1.5 h in an analogue tube roller (Bibby Scientifﬁc) at 4°C. This process
was repeated to diminish the urea concentration to 3, 1.5, and 0.5 M.
Finally, three cycles of dialysis were applied against 50 mL of EB.
Before and after refolding, the sampleswere assayed byﬂuorescence
(Supplementary Fig. 1).
2.12. Thermal stability using Thermoﬂuor assay
The proteins AAC, AACM.3, AACM.4, and AACM.3.4 were subjected
to thermoﬂuor assay [20], implemented using an ABI 7900 Real-Time
PCR (Applied Biosystems) system. Sypro Orange (Invitrogen) with
emission wavelength at 625 nm was used as a ﬂuorescent dye. Brieﬂy,. (a) AAC and AACM.3proteins; (b) AACM.4 andAACM.3.4 proteins. Lanes:MW:molecular
nd 6: pure proteins after refolding.
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and 5× SYPRO orange dye in EB buffer were used. The temperature
was increased from 25 to 95°C at a rate of 1°C/min. Equilibrium time
was 5 s for each temperature. All experiments were in triplicate,
melting curve analysis and determination of melting temperature (Tm)
were undertaken using Origin software (version 6.0) (Northampton).
2.13. 2-D electrophoresis
AAC and all modiﬁed variants were subjected to isoelectric focusing
using 7 cm immobilized strips of 3–10 pH gradient (Bio-Rad) in a
Protean i12 IEF system (Bio-Rad) to determine the isoelectric point
(pI) of the puriﬁed proteins [11].
3. Results and discussion
3.1. Expression and detection of AAC and its variants
Rosetta 2 (Novagen) and BL21-CodonPlus(DE3)-RIL (Stratagene) E.
coli strains were used to evaluate the expression of the AAC and their
modiﬁed variants at ﬂask level. SDS-PAGE data showed that the titers
of all variants of AAC were different in both strains. There was an
accumulative effect in all recombinant proteins for up to 6 h of
expression; the presence of these proteins was conﬁrmed by Western
blot (Fig. 2). The AAC and AACM.4 were expressed at high titers in
both strains at 24 h following induction in both strains (Fig. 2a and c).Fig. 6.Differentmelting curve proﬁles obtained for each recombinant protein by thermoﬂuor ass
(d): transition curves of AACM.4 and AACM.3.4 proteins, respectively. The insets in (a) and (c)
mean of triplicate experiments.Meanwhile AACM.3 and AACM.3.4 were expressed at lower titers
(Fig. 2b and d). The AACM.3 was not detected at 24 h in Rosetta 2
(Fig. 2b lane 5). The ANOVA data on densitometric values revealed
that the E. coli BL21-CodonPlus(DE3)-RIL was better for the expression
of all recombinant proteins.
The expression levels of AAC and AACM.4 expressed by
BL21-CodonPlus(DE3)-RIL did not show statistically signiﬁcant
differences (SSD) (P b 0.05) after 6 h. In contrast, proteins modiﬁed in
the third VR (AACM.3 and AACM.3.4) did not show SSD after 3 h of
expression; at 6 h SSD was clear. At 24 h after induction, all variants
showed SSD (P b 0.05) (Fig. 3a). According to the results, the level of
expression for recombinant proteins can be summarized as:
AAC≥AACM:4 NAACM:3 ≥AACM:3:4 ½Equation 1
According to titers and productivity (Fig. 3b), AAC and AACM.4 are
proteins that manifest greater in vivo or kinetic stability than AACM.3
and AACM.3.4. This might be because of modiﬁcations in the third VR.
The cultures were fractionated to deﬁne where the recombinant
proteins were accumulated at 6 h after induction. Soluble and
insoluble fractions are presented in Fig. 4. The AACM.4 protein
expressed by E. coli BL21-CodonPlus(DE3)-RIL manifested a higher
proportion in soluble form (approximately 5% of total protein titer)
than the other proteins. Most recombinant proteins were expressed
in insoluble form; the results were similar to those in the literature [9,
11,12].ay. (a) Transition curve of theAAC protein; (b) transition curve of AACM.3protein; (c) and
correspond to the plot of Tm values for AAC (34°C) and AACM.4 (37.2°C). Each value is the
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modiﬁed variants
Expression in E. coli BL21-CodonPlus(DE3)-RIL was scaled-up in a
bioreactor to increase the production yield for all the recombinant
proteins. The titers at 6 h after induction were AAC, 1.6 g/L; AACM.4,
1.55 g/L; AACM.3, 1.37 g/L and AACM.3.4, 1.32 g/L. These results are
3-fold higher than at the ﬂask level because the available oxygen was
increased by agitation and aeration. The cells harvested 6 h after
induction were disrupted to extract proteins. SDS-PAGE and Western
blot data are shown in Fig. 5. Recombinant proteins were expressed as
insoluble aggregates, which may be due to an increased translation rate
leading to protein misfolding and poor solubility [21]. Furthermore, the
insoluble fractions were used to purify the recombinant proteins by
IMAC. The AAC eluted at 5 mM imidazole. The AACM.3.4, AACM.3 and
AACM.4 eluted at 50 and 125 mM imidazole, respectively. Next, puriﬁed
proteins were refolded by applying dialysis to eliminate urea. The
percentages of refolded proteins according to initial concentration were
20% AAC, 18% AACM.3, 36% AACM.4, and 30% AACM.3.4. These
differences may be due to different conformations occurring in
recombinant proteins because of modiﬁcations with the biopeptides.
Fig. 5 shows the SDS-PAGE andWestern blot of all refolded pure proteins.
3.3. Thermal stability and 2-D electrophoresis
The Tm provides a quantitative indication of protein stability. Amore
stable protein will require higher temperatures to unfold [22]. All
proteins were subjected to a thermoﬂuor assay in EB, and Tm values
were 34.0 ± 0.11°C for AAC and 37.2 ± 0.2°C for AACM.4. This may
mean that AAC exposes its hydrophobic regions at lower temperatures
than AACM.4. Thus, AACM.4 is a more thermostable protein. By other
hand the absence of thermal transition curves in the VR3 mutants
may indicate that these proteins are unfolded, but the ﬂuorescence
spectra (Supplementary Fig. 1) indicated that they don't have the
same maximum emission wavelength after the urea were eliminated,
so they are partially folded. Thus, modiﬁcations in the third VR may
generate conformational changes that only enable solubilization of
these proteins by the refolding protocol such that AACM.3 and
AACM.3.4 remained as molten globule (Fig. 6). The fact that the
molten globules (VR3 mutants) were the lowest expressed by E. coli,
it's probably related to kinetic or in vivo stability.
Tandang-Silvas et al. [14] reported that thermal stability increases by
diminishing the loop length, but for AACM.4 the insertion of bioactive
peptides into the fourth VR increases the loop. Here, thermal stability
is greater than that of the AAC. Perhaps the insertion of bioactive
peptides in AACM.4 enhances thermal stability because it generates
interactions that stabilize the protein.
The 2-D electrophoresis demonstrated that the pl of AAC is 6, whereas
AACM.3, AACM.4, and AACM.3.4 are 6.1, 5.93, and 6.3, respectively. These
results are close to those calculated via the ProtParam tool.
In conclusion, there are differences in the expression and recovered
percentage based on the refolding protocol of recombinant proteins. This
may be due to structural modiﬁcations due to the insertions done in the
molecule. They are also reﬂected in properties such as thermal stability.
It is well known that mutations by amino acid insertions in
secondary structure elements tend to be more susceptible to
destabilization of proteins [23]. Nevertheless, in this research variable
regions (unstructured regions) were chosen to carry out mutations to
decrease this possibility; even so, insertions in third variable region
(VR3) destabilize the structure.
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